This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
ReportsnReports.com adds OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 Event-Driven Update to its store. The majority of Cystic Fibrosis sales will come from the US, which will represent 60% of the market by 2018.
Dallas, TX (PRWEB) July 16, 2014
Researcher estimates the 2012 sales for Cystic Fibrosis to be approximately $1.2 billion across the six markets covered in this forecast: the US, France, Germany, Italy, Spain and the UK. By the end of the forecast period, sales will grow to approximately $5.3 billion, with a CAGR of 28.96%. The majority of sales will come from the US, which will represent 60% of the market by 2018.
Cystic Fibrosis (CF) is an autosomal recessive disease characterized by the secretion of thick, sticky mucus which clogs the lungs and leads to life-threatening lung infections; and obstructs pancreatic enzyme secretions that are essential for the body to break down and absorb nutrients. CF patients have a limited number of available treatment options and significant unmet needs still exist. Opportunities are significant for new therapies that will improve symptoms, change the course of this disease, as well as increase therapy options. The introduction of the first disease modifying therapy, Kalydeco (ivacaftor), by Vertex in 2012, paved the way for a new class of therapies known as cystic fibrosis transmembrane conductance regulator (CFTR) modulators. On June 24, 2014, Vertex announced positive Phase III clinical trial data for lumacaftor in combination with Kalydeco in patients with CF who have two copies of the F508del mutation. This novel combination therapy of CFTR modulators has the potential to treat the underlying cause of the disease for approximately 50% of all CF patients and drive rapid growth in the CF market.
Key Questions Answered
Order a purchase copy of this report @ http://www.reportsnreports.com/Purchase.aspx?name=292044.
Request a sample copy @ http://www.reportsnreports.com/contacts/RequestSample.aspx?name=292044.
Reasons to buy
Table of Contents
1 Table of Contents
3 Disease Overview
5 Current Treatment Options
6 Unmet Needs Assessment and Oppportunity Analysis
7 R&D Strategies
8 Pipeline Assessment
9 Pipeline Valuation Analysis
Explore more reports on Pharmaceuticals industry at http://www.reportsnreports.com/market-research/pharmaceuticals/.
ReportsnReports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
For the original version on PRWeb visit: http://www.prweb.com/releases/cystic-fibrosis-market/analysis-forecasts-2018/prweb12022260.htm
Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact email@example.com.